Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Recovery of sense of smell (as · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
It is very uncertain whether palmitoylethanolamide and luteolin changes recovery of sense of smell (as compared with no intervention (very low certainty).
1 finding from 1 review
Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of normal olfactory function · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
It is very uncertain whether intranasal steroid spray changes presence of normal olfactory function Assessed by participants as a… compared with no intervention/placebo (very low certainty).
2 findings from 1 review
Other adverse effects · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
3 findings from 1 review
no estimate extracted
1 study · 77 participants
Very low
no estimate extracted
1 study · 100 participants
Very low
no estimate extracted
1 study · 77 participants
Low
Prevalence of parosmia · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in taste · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review